OBJECTIVES: Vascular endothelial growth factor (VEGF), a potent angiogenic mediator, can be delivered to targeted tissues by means of a replication-deficient adenovirus (Ad) vector. We hypothesized that direct administration of Ad vector expressing the VEGF121 complementary deoxyribonucleic acid (AdGVVEGF121.10) into regions of ischemic myocardium would enhance collateral vessel formation and improve regional perfusion and function. METHODS: Yorkshire swine underwent thoracotomy and placement of an Ameroid constrictor (Research Instruments & MFG, Corvallis, Ore.) on the circumflex coronary artery. Three weeks later, myocardial perfusion and function were assessed by single photon emission computed tomography imaging (SPECT) with 99mTc-labeled sestamibi and by echocardiography during rest and stress. AdGVVEGF121.10 (n = 7) or the control vector, AdNull (n = 8), was administered directly into the myocardium at 10 sites in the circumflex distribution (10(8) pfu/site). Four weeks later, these studies were repeated and ex vivo angiography was performed. RESULTS: SPECT imaging 4 weeks after vector administration demonstrated significant reduction in the ischemic area at stress in AdGVVEFG121.10-treated animals compared with AdNull control animals (p = 0.005). Stress echocardiography at the same time demonstrated improved segmental wall thickening in AdGVVEGF121.10 animals compared with AdNull control animals (p = 0.03), with AdGVVEGF121.10 animals showing nearly normalized function in the circumflex distribution. Collateral vessel development assessed by angiography was also significantly greater in AdGVVEGF121.10 animals than in AdNull control animals (p = 0.04), with almost complete reconstitution of circumflex filling in AdGVVEGF121.10 animals. CONCLUSIONS: An Ad vector expressing the VEGF121 cDNA induces collateral vessel development in ischemic myocardium and results in significant improvement in both myocardial perfusion and function. Such a strategy may be useful in patients with ischemic heart disease in whom complete revascularization is not possible.
OBJECTIVES: Vascular endothelial growth factor (VEGF), a potent angiogenic mediator, can be delivered to targeted tissues by means of a replication-deficient adenovirus (Ad) vector. We hypothesized that direct administration of Ad vector expressing the VEGF121 complementary deoxyribonucleic acid (AdGVVEGF121.10) into regions of ischemic myocardium would enhance collateral vessel formation and improve regional perfusion and function. METHODS: Yorkshire swine underwent thoracotomy and placement of an Ameroid constrictor (Research Instruments & MFG, Corvallis, Ore.) on the circumflex coronary artery. Three weeks later, myocardial perfusion and function were assessed by single photon emission computed tomography imaging (SPECT) with 99mTc-labeled sestamibi and by echocardiography during rest and stress. AdGVVEGF121.10 (n = 7) or the control vector, AdNull (n = 8), was administered directly into the myocardium at 10 sites in the circumflex distribution (10(8) pfu/site). Four weeks later, these studies were repeated and ex vivo angiography was performed. RESULTS: SPECT imaging 4 weeks after vector administration demonstrated significant reduction in the ischemic area at stress in AdGVVEFG121.10-treated animals compared with AdNull control animals (p = 0.005). Stress echocardiography at the same time demonstrated improved segmental wall thickening in AdGVVEGF121.10 animals compared with AdNull control animals (p = 0.03), with AdGVVEGF121.10 animals showing nearly normalized function in the circumflex distribution. Collateral vessel development assessed by angiography was also significantly greater in AdGVVEGF121.10 animals than in AdNull control animals (p = 0.04), with almost complete reconstitution of circumflex filling in AdGVVEGF121.10 animals. CONCLUSIONS: An Ad vector expressing the VEGF121 cDNA induces collateral vessel development in ischemic myocardium and results in significant improvement in both myocardial perfusion and function. Such a strategy may be useful in patients with ischemic heart disease in whom complete revascularization is not possible.
Authors: C J Magovern; C A Mack; J Zhang; R T Hahn; W Ko; O W Isom; R G Crystal; T K Rosengart Journal: Ann Thorac Surg Date: 1996-08 Impact factor: 4.330
Authors: K Harada; M Friedman; J J Lopez; S Y Wang; J Li; P V Prasad; J D Pearlman; E R Edelman; F W Sellke; M Simons Journal: Am J Physiol Date: 1996-05
Authors: A Kass-Eisler; E Falck-Pedersen; M Alvira; J Rivera; P M Buttrick; B A Wittenberg; L Cipriani; L A Leinwand Journal: Proc Natl Acad Sci U S A Date: 1993-12-15 Impact factor: 11.205
Authors: S Banai; M T Jaklitsch; W Casscells; M Shou; S Shrivastav; R Correa; S E Epstein; E F Unger Journal: Circ Res Date: 1991-07 Impact factor: 17.367
Authors: C A Mack; W R Song; H Carpenter; T J Wickham; I Kovesdi; B G Harvey; C J Magovern; O W Isom; T Rosengart; E Falck-Pedersen; N R Hackett; R G Crystal; A Mastrangeli Journal: Hum Gene Ther Date: 1997-01-01 Impact factor: 5.695
Authors: M D Hariawala; J R Horowitz; D Esakof; D D Sheriff; D H Walter; B Keyt; J M Isner; J F Symes Journal: J Surg Res Date: 1996-06 Impact factor: 2.192
Authors: S Takeshita; L P Zheng; E Brogi; M Kearney; L Q Pu; S Bunting; N Ferrara; J F Symes; J M Isner Journal: J Clin Invest Date: 1994-02 Impact factor: 14.808
Authors: Clare R Ozawa; Andrea Banfi; Nicole L Glazer; Gavin Thurston; Matthew L Springer; Peggy E Kraft; Donald M McDonald; Helen M Blau Journal: J Clin Invest Date: 2004-02 Impact factor: 14.808